Seelos Therapeutics Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seelos Therapeutics stock.
View analyst ratings for Seelos Therapeutics or view top-rated stocks.

Wall Street analysts have given Seelos Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seelos Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Seelos Therapeutics.

Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SEEL shares have increased by 574.4% and is now trading at $5.26.
View which stocks have been most impacted by COVID-19.

3 analysts have issued 1 year price targets for Seelos Therapeutics' stock. Their forecasts range from $12.00 to $15.00. On average, they expect Seelos Therapeutics' share price to reach $13.67 in the next year. This suggests a possible upside of 159.8% from the stock's current price.
View analysts' price targets for Seelos Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Seelos Therapeutics include Myovant Sciences (MYOV), Heron Therapeutics (HRTX), ADC Therapeutics (ADCT), Harmony Biosciences (HRMY), Generation Bio (GBIO), Aurinia Pharmaceuticals (AUPH), uniQure (QURE), Travere Therapeutics (TVTX), ImmunoGen (IMGN), Prelude Therapeutics (PRLD), DiaMedica Therapeutics (DMCAF), Applied Molecular Transport (AMTI), Olema Pharmaceuticals (OLMA), PMV Pharmaceuticals (PMVP) and Endo International (ENDP).
View all of SEEL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SEEL stock can currently be purchased for approximately $5.26.

Seelos Therapeutics has a market capitalization of $411.77 million and generates $380,000.00 in revenue each year.

Seelos Therapeutics employs 8 workers across the globe.

The official website for Seelos Therapeutics is www.seelostherapeutics.com.

Seelos Therapeutics is headquartered at 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022.

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at (646) 293-2100 or via email at [email protected]